Please assess the completion status of the following clinical trial:

Trial Title: Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with Bipolar Disorder~* Must be able to swallow tablets~Exclusion Criteria:~* Children with general medical condition such as head injury, epilepsy, endocrine disorders~* Those who are on mood altering medications such as steroids, and those diagnosed with mental retardation are excluded to avoid confounding and contributing factors to mood swings.~* If we discover during the interview that the parent and/or child does not understand the consent/assent procedures, we will exclude them.~We expect only a small number of children to be excluded from the study due to exclusionary criteria. Selection of the subjects is not based on sex, race, or ethnic group.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone (Type: ACTIVE_COMPARATOR): Risperidone is an antimanic medication and is a second generation antipsychotic
- Divalproex sodium (Type: ACTIVE_COMPARATOR): Divalproex sodium is an antiepileptic medication and is a mood stabilizer

Based on this trial design, predict the completion outcome and termination type (if applicable).